vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.
Forestar Group Inc. is the larger business by last-quarter revenue ($273.0M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 5.6%, a 5.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-157.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -9.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
ANIP vs FOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $273.0M |
| Net Profit | $27.5M | $15.4M |
| Gross Margin | — | 20.1% |
| Operating Margin | 14.1% | 7.6% |
| Net Margin | 11.1% | 5.6% |
| Revenue YoY | 29.6% | 9.0% |
| Net Profit YoY | 367.5% | -6.7% |
| EPS (diluted) | $1.14 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $273.0M | ||
| Q3 25 | $227.8M | $670.5M | ||
| Q2 25 | $211.4M | $390.5M | ||
| Q1 25 | $197.1M | $351.0M | ||
| Q4 24 | $190.6M | $250.4M | ||
| Q3 24 | $148.3M | $551.3M | ||
| Q2 24 | $138.0M | $318.4M | ||
| Q1 24 | $137.4M | $333.8M |
| Q4 25 | $27.5M | $15.4M | ||
| Q3 25 | $26.6M | $86.9M | ||
| Q2 25 | $8.5M | $32.9M | ||
| Q1 25 | $15.7M | $31.6M | ||
| Q4 24 | $-10.3M | $16.5M | ||
| Q3 24 | $-24.2M | $81.5M | ||
| Q2 24 | $-2.3M | $38.7M | ||
| Q1 24 | $18.2M | $45.0M |
| Q4 25 | — | 20.1% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 20.4% | ||
| Q1 25 | — | 22.6% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 22.5% | ||
| Q1 24 | — | 24.9% |
| Q4 25 | 14.1% | 7.6% | ||
| Q3 25 | 15.9% | 16.9% | ||
| Q2 25 | 6.6% | 11.2% | ||
| Q1 25 | 13.3% | 11.6% | ||
| Q4 24 | -2.3% | 8.7% | ||
| Q3 24 | -13.8% | 19.7% | ||
| Q2 24 | 3.7% | 16.2% | ||
| Q1 24 | 14.8% | 17.6% |
| Q4 25 | 11.1% | 5.6% | ||
| Q3 25 | 11.7% | 13.0% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 9.0% | ||
| Q4 24 | -5.4% | 6.6% | ||
| Q3 24 | -16.3% | 14.8% | ||
| Q2 24 | -1.7% | 12.2% | ||
| Q1 24 | 13.2% | 13.5% |
| Q4 25 | $1.14 | $0.30 | ||
| Q3 25 | $1.13 | $1.70 | ||
| Q2 25 | $0.36 | $0.65 | ||
| Q1 25 | $0.69 | $0.62 | ||
| Q4 24 | $-0.45 | $0.32 | ||
| Q3 24 | $-1.27 | $1.59 | ||
| Q2 24 | $-0.14 | $0.76 | ||
| Q1 24 | $0.82 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $211.7M |
| Total DebtLower is stronger | — | $793.2M |
| Stockholders' EquityBook value | $540.7M | $1.8B |
| Total Assets | $1.4B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $211.7M | ||
| Q3 25 | $262.6M | $379.2M | ||
| Q2 25 | $217.8M | $189.2M | ||
| Q1 25 | $149.8M | $174.3M | ||
| Q4 24 | $144.9M | $132.0M | ||
| Q3 24 | $145.0M | $481.2M | ||
| Q2 24 | $240.1M | $359.2M | ||
| Q1 24 | $228.6M | $416.2M |
| Q4 25 | — | $793.2M | ||
| Q3 25 | — | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.6B | ||
| Q4 24 | $403.7M | $1.6B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.5B | ||
| Q1 24 | $452.0M | $1.5B |
| Q4 25 | $1.4B | $3.2B | ||
| Q3 25 | $1.4B | $3.1B | ||
| Q2 25 | $1.3B | $3.1B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.3B | $3.0B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $920.8M | $2.7B | ||
| Q1 24 | $914.5M | $2.6B |
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-157.0M |
| Free Cash FlowOCF − Capex | $29.1M | $-157.1M |
| FCF MarginFCF / Revenue | 11.8% | -57.5% |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.10× | -10.19× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-157.0M | ||
| Q3 25 | $44.1M | $256.3M | ||
| Q2 25 | $75.8M | $15.8M | ||
| Q1 25 | $35.0M | $-19.8M | ||
| Q4 24 | $15.9M | $-450.0M | ||
| Q3 24 | $12.5M | $119.2M | ||
| Q2 24 | $17.4M | $-61.7M | ||
| Q1 24 | $18.3M | $-59.2M |
| Q4 25 | $29.1M | $-157.1M | ||
| Q3 25 | $38.0M | $255.6M | ||
| Q2 25 | $71.8M | $15.0M | ||
| Q1 25 | $32.5M | $-20.5M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $118.4M | ||
| Q2 24 | $13.0M | $-62.3M | ||
| Q1 24 | $13.7M | $-59.8M |
| Q4 25 | 11.8% | -57.5% | ||
| Q3 25 | 16.7% | 38.1% | ||
| Q2 25 | 34.0% | 3.8% | ||
| Q1 25 | 16.5% | -5.8% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 21.5% | ||
| Q2 24 | 9.4% | -19.6% | ||
| Q1 24 | 10.0% | -17.9% |
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 2.7% | 0.1% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | -10.19× | ||
| Q3 25 | 1.66× | 2.95× | ||
| Q2 25 | 8.87× | 0.48× | ||
| Q1 25 | 2.23× | -0.63× | ||
| Q4 24 | — | -27.27× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | -1.59× | ||
| Q1 24 | 1.00× | -1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
